









Markets
/
Stocks
/
nasdaq-cmps
/

Compass Pathways PLC

CMPS

View Detailed Chart

4.340USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

406.16MMarket Cap

LossP/E TTM



Compass Pathways PLC

4.340

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-0.23%

5 Days

+0.23%

1 Month

+33.13%

6 Months

+0.70%

Year to Date

+14.81%

1 Year

-38.35%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts

BUY

Current Rating

16.000

Target Price

268.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Compass Pathways PLC

CMPS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(3)

Buy(8)

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.051

Buy

RSI(14)

56.517

Neutral

STOCH(KDJ)(9,3,3)

46.520

Neutral

ATR(14)

0.376

High Vlolatility

CCI(14)

38.549

Neutral

Williams %R

34.375

Buy

TRIX(12,20)

0.821

Sell

StochRSI(14)

80.126

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.252

Buy

MA10

4.346

Sell

MA20

4.027

Buy

MA50

4.003

Buy

MA100

3.719

Buy

MA200

4.124

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Ticker SymbolCMPS

CompanyCompass Pathways PLC

CEOMr. Kabir Nath

Websitehttps://compasspathways.com/